About Forte Medical Forte Medical is a UK-based medical technology company dedicated to improving specimen collection and diagnostic accuracy across primary and secondary care. Its mission is to ...

A plant-based fiber that feeds the good bacteria in your gut, XOS ensures that the probiotic strains in Bioma thrive and ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...

Sales within Diabetes and Obesity care increased by 16% in Danish kroner to DKK 145.4 billion (18% at CER), mainly driven by Obesity care growth of 56% in Danish kroner to DKK 38.8 billion (58% at CER ...

Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds.

Sanofi completes the acquisition of Vigil Neuroscience, Inc.

The full publication, which includes additional details such as patient demographics, inclusion/exclusion criteria, and complications reported in the studies, is available on the Journal of Foot & ...

Ireland represents both a new territory and OPSB’s first international market. This location is complimentary to OrthoPediatrics’ strong implant business presence in one of the country’s largest ...

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central ...

GAAP Financial Information” below. “Throughout the second quarter, we continued to make important progress advancing our 5x30 growth strategy to accelerate topline growth and fuel our transition into ...

Net Loss For the second quarter of 2025, Ultragenyx reported net loss of $115 million, or $1.17 per share basic and diluted, compared with a net loss for the second quarter of 2024 of $132 million, or ...

Industry leader Michael Vasconcelles, M.D., joined Day One in June 2025 as Head of Research and Development. Dr. Vasconcelles brings more than 25 years of extensive oncology research and development ...